| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anna R Malik, Ewa Liszewska, Agnieszka Skalecka, Malgorzata Urbanska, Anand M Iyer, Lukasz J Swiech, Malgorzata Perycz, Kamil Parobczak, Patrycja Pietruszka, Malgorzata M Zarebska, Matylda Macias, Katarzyna Kotulska, Julita Borkowska, Wieslawa Grajkowska, Magdalena E Tyburczy, Sergiusz Jozwiak, David J Kwiatkowski, Eleonora Aronica, Jacek Jaworsk. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase. Acta neuropathologica communications. vol 3. 2016-04-21. PMID:26220190. |
tuberous sclerosis complex (tsc) is a genetic disease resulting from mutation in tsc1 or tsc2 and subsequent hyperactivation of mammalian target of rapamycin (mtor). |
2016-04-21 |
2023-08-13 |
Not clear |
| Elżbieta Radzikowsk. Lymphangioleiomyomatosis: New Treatment Perspectives. Lung. vol 193. issue 4. 2016-04-14. PMID:25980593. |
mutations in the tuberous sclerosis complex genes, lead to the activation of mammalian target of rapamycin kinase (mtor), results in proliferation of lam cells, its increasing motility, and survival. |
2016-04-14 |
2023-08-13 |
Not clear |
| Angelika Mühlebner, Anand M Iyer, Jackelien van Scheppingen, Jasper J Anink, Floor E Jansen, Tim J Veersema, Kees P Braun, Wim G M Spliet, Wim van Hecke, Figen Söylemezoğlu, Martha Feucht, Pavel Krsek, Josef Zamecnik, Christian G Bien, Tilman Polster, Roland Coras, Ingmar Blümcke, Eleonora Aronic. Specific pattern of maturation and differentiation in the formation of cortical tubers in tuberous sclerosis omplex (TSC): evidence from layer-specific marker expression. Journal of neurodevelopmental disorders. vol 8. 2016-04-04. PMID:27042238. |
tuberous sclerosis complex (tsc) is a multisystem disorder that results from mutations in the tsc1 or tsc2 genes, leading to constitutive activation of the mammalian target of rapamycin (mtor) signaling pathway. |
2016-04-04 |
2023-08-13 |
Not clear |
| Rahul A Sheth, Adam S Feldman, Elahna Paul, Elizabeth A Thiele, T Gregory Walke. Angiographic and volumetric effects of mammalian target of rapamycin inhibitors on angiomyolipomas in tuberous sclerosis. World journal of radiology. vol 8. issue 3. 2016-03-31. PMID:27027863. |
to investigate the angiographic and volumetric effects of mammalian target of rapamycin (mtor) inhibitors on angiomyolipomas (amls) in a case series of patients with tuberous sclerosis complex. |
2016-03-31 |
2023-08-13 |
Not clear |
| Ramesh M Ray, Mitul Bavaria, Leonard R Johnso. Interaction of polyamines and mTOR signaling in the synthesis of antizyme (AZ). Cellular signalling. vol 27. issue 9. 2016-03-29. PMID:26093026. |
tuberous sclerosis protein (tsc), a negative regulator of mtor function regulates the activities of both the torc1 and torc2. |
2016-03-29 |
2023-08-13 |
Not clear |
| Lily H Tran, Mary L Zupan. Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature. Pediatric neurology. vol 53. issue 1. 2016-03-28. PMID:26092412. |
everolimus is an mtor inhibitor approved for use in a number of indications where mtor overactivation is implicated, including tuberous sclerosis complex. |
2016-03-28 |
2023-08-13 |
Not clear |
| Gareth Baynam, Angela Overkov, Mark Davis, Kym Mina, Lyn Schofield, Richard Allcock, Nigel Laing, Matthew Cook, Hugh Dawkins, Jack Goldblat. A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces. American journal of medical genetics. Part A. vol 167. issue 7. 2016-03-17. PMID:25851998. |
we describe the findings in this family to highlight that (i) the path to determination of pathogenicity was confounded by the lack of genomic reference data for australian aboriginals and that (ii) the disease biology, functional analyses in this family, and studies on the tuberous sclerosis complex support consideration of an mtor inhibitor as a therapeutic agent. |
2016-03-17 |
2023-08-13 |
human |
| Michael J G Somers, Elahna Pau. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. Journal of clinical pharmacology. vol 55. issue 4. 2016-03-14. PMID:25402866. |
the oral mtor inhibitor everolimus was recently approved for the treatment of tuberous sclerosis complex (tsc)-associated renal angiomyolipoma. |
2016-03-14 |
2023-08-13 |
Not clear |
| Xiaoqiu Wang, Robert C Burghardt, Jared J Romero, Thomas R Hansen, Guoyao Wu, Fuller W Baze. Functional roles of arginine during the peri-implantation period of pregnancy. III. Arginine stimulates proliferation and interferon tau production by ovine trophectoderm cells via nitric oxide and polyamine-TSC2-MTOR signaling pathways. Biology of reproduction. vol 92. issue 3. 2016-02-22. PMID:25653279. |
it also increased phosphorylated tuberous sclerosis protein (p-tsc2) and phosphorylated mechanistic target of rapamycin (mtor) abundance by more than 2.7- and 4.3-fold (p < 0.0001) after long-term incubation, respectively. |
2016-02-22 |
2023-08-13 |
Not clear |
| Víctor L Ruggieri, Claudia L Arbera. [Therapeutic approaches in autism spectrum disorders]. Revista de neurologia. vol 60 Suppl 1. 2016-02-22. PMID:25726823. |
these entities include fragile x syndrome (gabaergic and metabotropic glutamate receptor inhibitors), tuberous sclerosis (mtor inhibitors), phelan-mcdermid syndrome and rett syndrome (insulin-like growth factor 1 inhibitors). |
2016-02-22 |
2023-08-13 |
Not clear |
| Krzysztof Sadowski, Katarzyna Kotulska-Jóźwiak, Sergiusz Jóźwia. Role of mTOR inhibitors in epilepsy treatment. Pharmacological reports : PR. vol 67. issue 3. 2016-02-12. PMID:25933981. |
the mammalian target of rapamycin (mtor) pathway is involved in highly epileptogenic conditions, such as tuberous sclerosis complex (tsc) and represents a reasonable target for antiepileptogenic interventions. |
2016-02-12 |
2023-08-13 |
Not clear |
| Hung Huynh, Huai-Xiang Hao, Stephen L Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David Yang, David Ruddy, Manway Liu, Adnan Derti, Marissa N Balak, Michael R Palmer, Yan Wang, Benjamin H Lee, Dalila Sellami, Andrew X Zhu, Robert Schlegel, Alan Huan. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular cancer therapeutics. vol 14. issue 5. 2016-02-01. PMID:25724664. |
tuberous sclerosis complex (tsc), a heterodimer of tsc1 and tsc2, functions as a negative regulator of mtor signaling. |
2016-02-01 |
2023-08-13 |
Not clear |
| Jessica A Burket, Andrew D Benson, Amy H Tang, Stephen I Deutsc. NMDA receptor activation regulates sociability by its effect on mTOR signaling activity. Progress in neuro-psychopharmacology & biological psychiatry. vol 60. 2016-01-22. PMID:25703582. |
interestingly, the severity of the intellectual disability in tuberous sclerosis complex may relate more to this metabolic disturbance (i.e., overactivity of mtor signaling) than the density of cortical tubers. |
2016-01-22 |
2023-08-13 |
mouse |
| Kimberly M Huber, Eric Klann, Mauro Costa-Mattioli, R Suzanne Zuki. Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 35. issue 41. 2016-01-19. PMID:26468183. |
dysregulation of mtor signaling has been identified as a phenotypic feature common to fragile x syndrome, tuberous sclerosis complex 1 and 2, neurofibromatosis 1, phosphatase and tensin homolog, and potentially rett syndrome. |
2016-01-19 |
2023-08-13 |
mouse |
| Yanhui Xu, Ziru Li, Yue Yin, He Lan, Jun Wang, Jing Zhao, Juan Feng, Yin Li, Weizhen Zhan. Ghrelin inhibits the differentiation of T helper 17 cells through mTOR/STAT3 signaling pathway. PloS one. vol 10. issue 2. 2016-01-13. PMID:25658305. |
activation of mtor signaling by injection of cre-expressiong adenovirus into tuberous sclerosis complex 1 (tsc1) loxp/loxp mice increased the differentiation of th17 cells in spleen, which was associated with an increment in the phosphorylation of stat3. |
2016-01-13 |
2023-08-13 |
mouse |
| Isabelle Goyer, Nagib Dahdah, Philippe Majo. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatric neurology. vol 52. issue 4. 2016-01-13. PMID:25682485. |
use of mtor inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. |
2016-01-13 |
2023-08-13 |
Not clear |
| Isabelle Goyer, Nagib Dahdah, Philippe Majo. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatric neurology. vol 52. issue 4. 2016-01-13. PMID:25682485. |
tuberous sclerosis complex is characterized by the growth of benign tumors in multiple organs, caused by the disinhibition of the mammalian target of rapamycin (mtor) protein. |
2016-01-13 |
2023-08-13 |
Not clear |
| Isabelle Goyer, Nagib Dahdah, Philippe Majo. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatric neurology. vol 52. issue 4. 2016-01-13. PMID:25682485. |
mtor inhibitors, such as everolimus, are used in patients with tuberous sclerosis complex, mainly to reduce the size of renal angiomyolipomas and subependymal giant cell astrocytomas. |
2016-01-13 |
2023-08-13 |
Not clear |
| Myungjin Kim, Jun Hee Le. Identification of an AMPK phosphorylation site in Drosophila TSC2 (gigas) that regulate cell growth. International journal of molecular sciences. vol 16. issue 4. 2016-01-04. PMID:25826530. |
one of the ampk substrates, tuberous sclerosis complex 2 (tsc2), was suggested to mediate ampk-induced silencing of mtor complex 1 (mtorc1) signaling that is critical for cell growth. |
2016-01-04 |
2023-08-13 |
drosophila_melanogaster |
| Peter B Crin. mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harbor perspectives in medicine. vol 5. issue 4. 2015-12-29. PMID:25833943. |
mutations in mtor regulatory genes (e.g., tsc1, tsc2, akt3, depdc5) have been associated with several focal mcd highly associated with epilepsy such as tuberous sclerosis complex (tsc), hemimegalencephaly (hme; brain malformation associated with dramatic enlargement of one brain hemisphere), and cortical dysplasia. |
2015-12-29 |
2023-08-13 |
Not clear |